Brooks Laboratories Limited (BROOKS) AI Stock Analysis

• Market Cap: ₹4.03B
• Dividend Yield: N/A
• Average Volume (3M): 5.71K
• Price to Earnings (P/E): 313.5
• Beta (1Y): 1.33
• Revenue Growth: 10.30%
• EPS Growth: N/A
• Country: IN
• Employees: 293
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 3.25
• Shares Outstanding: 29,457,249
• 10 Day Avg. Volume: 2,486
• 30 Day Avg. Volume: 5,711
• PEG Ratio: 0.59
• Price to Book (P/B): 3.42
• Price to Sales (P/S): 4.06
• P/FCF Ratio: -3.45K
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹137.00
• Price Target Upside: 0.15% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 42 Neutral
• Price Target: ₹137.00 ▲(0.15% Upside)

Brooks Laboratories Limited's overall stock score is primarily impacted by its weak financial performance and technical indicators. The high P/E ratio suggests overvaluation, and the lack of dividend yield further detracts from its appeal. The absence of positive earnings call insights or corporate events leaves the stock with limited upside potential in the near term.

Brooks Laboratories Limited Business Overview & Revenue Model

Company Description

Brooks Laboratories Limited manufactures and sells pharmaceuticals on contract basis in India and internationally. It offers carbapenem drugs; tablets; dry syrup; liquid and dry power injections; and eye and ear drop. Brooks Laboratories Limited was incorporated in 2002 and is based in Mumbai, India.

How the Company Makes Money

Brooks Laboratories Limited generates revenue through the sale of its pharmaceutical products, which include a wide range of formulations across different therapeutic segments. The company's primary revenue streams come from its domestic sales within India and exports to international markets. Brooks Laboratories also engages in contract manufacturing for other pharmaceutical companies, providing additional income. Strategic partnerships and collaborations with other pharmaceutical firms and research institutions further enhance its revenue capabilities by expanding its market reach and product offerings.

Brooks Laboratories Limited Financial Statement Overview

Summary

Brooks Laboratories Limited faces challenges with financial stability and profitability, with negative net income and cash flow issues. Despite improvements in margins and debt management, revenue volatility and negative cash flow remain concerns.

Income Statement

Brooks Laboratories Limited has shown inconsistent revenue growth, with a noticeable decline in revenue from 2022 to 2023, followed by a recovery in 2025. Gross profit margins have been volatile, indicating instability in cost management. However, the company has managed to improve its EBIT and EBITDA margins in 2025 compared to previous years, although net profit margins remain negative due to persistent net losses.

Balance Sheet

The company's debt-to-equity ratio has improved as total debt decreased over recent years, suggesting better leverage management. The return on equity remains negative due to ongoing net losses, which is a concern. However, the equity ratio is relatively stable, indicating a strong equity position relative to total assets.

Cash Flow

Cash flow from operations has been negative for several years, but there has been some improvement in 2025. The company has struggled with free cash flow, indicating potential liquidity issues. The operating cash flow to net income ratio remains unfavorable due to sustained losses, although free cash flow has shown slight growth from a very low base.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2020
Income Statement
Total Revenue	948.95M	825.57M	790.12M	632.05M	900.93M	691.33M
Gross Profit	288.76M	139.22M	60.88M	126.02M	142.94M	156.56M
EBITDA	-73.45M	58.22M	41.73M	-291.68M	-134.50M	-35.16M
Net Income	-205.54M	-99.67M	-195.92M	-209.00M	-193.13M	-243.76M
Balance Sheet
Total Assets	0.00	1.24B	904.45M	1.10B	1.96B	1.58B
Cash, Cash Equivalents and Short-Term Investments	8.08M	12.48M	1.25M	13.78M	23.85M	3.96M
Total Debt	0.00	75.83M	56.42M	65.12M	252.59M	276.36M
Total Liabilities	-592.09M	255.90M	248.60M	356.44M	615.91M	594.48M
Stockholders Equity	592.09M	981.04M	655.85M	739.53M	630.51M	984.16M
Cash Flow
Free Cash Flow	0.00	-971.00K	-101.20M	-149.58M	-650.53M	-119.72M
Operating Cash Flow	0.00	17.62M	-96.81M	-144.91M	-374.41M	-93.89M
Investing Cash Flow	0.00	-460.41M	1.82M	4.95M	-249.09M	-23.26M
Financing Cash Flow	0.00	441.96M	96.01M	114.14M	640.71M	96.12M

Brooks Laboratories Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 136.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BROOKS, the sentiment is Negative. The current price of 136.8 is below the 20-day moving average (MA) of 147.47, below the 50-day MA of 150.35, and below the 200-day MA of 143.40, indicating a bearish trend. The MACD of -1.32 indicates Positive momentum. The RSI at 35.32 is Neutral, neither overbought nor oversold. The STOCH value of 7.45 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BROOKS.

Brooks Laboratories Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MEDICO	66 Neutral	₹4.00B	39.66	16.16%	―	4.15%	21.74%
ALBERTDAVD	65 Neutral	₹4.45B	70.70	4.38%	0.64%	-9.14%	-91.11%
MEDICAMEQ	54 Neutral	₹4.13B	41.20	3.34%	0.33%	-9.90%	33.18%
ZIMLAB	54 Neutral	₹3.57B	38.06	4.82%	―	-3.36%	-47.58%
NECLIFE	43 Neutral	₹3.26B	-1.81	-11.89%	―	-3.41%	-3028.44%
BROOKS	42 Neutral	₹4.03B	313.47	―	―	10.30%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%